Sohini Das And Ruchika Chitravanshi

Stories by Sohini Das And Ruchika Chitravanshi

India could get 4th Covid vaccine as Zydus Cadila set to seek nod for ZyCoV-D

India could get 4th Covid vaccine as Zydus Cadila set to seek nod for ZyCoV-D

Rediff.com   14 Jun 2021

This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das

FAQ: Is it safe to take antibody cocktail for Covid-19?

FAQ: Is it safe to take antibody cocktail for Covid-19?

Rediff.com   10 Jun 2021

According to medical practitioners, the treatment is especially useful in controlling disease among those who have not received the vaccine or got only one shot and also the high-risk contacts of a patient.

Study comparing Covishield, Covaxin has limitations: Bharat Biotech

Study comparing Covishield, Covaxin has limitations: Bharat Biotech

Rediff.com   9 Jun 2021

Raches Ella, project lead, Covid-19 vaccines at Bharat Biotech said in a series of tweets that he was 'surprised' that media and researchers were drawing conclusions based on non-peer reviewed work.

COVID-19 Vaccine: 4 months from lab to jab

COVID-19 Vaccine: 4 months from lab to jab

Rediff.com   8 Jun 2021

'Almost 70 per cent production time of a vaccine is dedicated to quality control, which is done through several hundred tests.'

Covishield produced more antibodies than Covaxin: Study

Covishield produced more antibodies than Covaxin: Study

Rediff.com   7 Jun 2021

The study by a group of doctors showed that after two shots of the vaccines, 98 per cent recipients of Covishield showed antibody response, while the same was 80 per cent among Covaxin recipients. Sohini Das and Ruchika Chitravanshi report.

Biological E inks deal with Canadian firm for mRNA Covid vaccine

Biological E inks deal with Canadian firm for mRNA Covid vaccine

Rediff.com   2 Jun 2021

Providence will sell up to 30 mn doses of its mRNA vaccine to Biological E. It would also provide the necessary technology transfer to make the vaccine in India, with a minimum production capacity of 600 mn doses in 2022 and targets capacity of 1 bn doses, reports Sohini Das.

Centre recommends 3-pronged strategy for states to unlock

Centre recommends 3-pronged strategy for states to unlock

Rediff.com   2 Jun 2021

States should ensure a weekly positivity rate of less than 5 per cent, vaccination coverage of at least 70 per cent among the vulnerable section, and community ownership of Covid-appropriate behaviour, reports Ruchika Chitravanshi.

Bharat Biotech to make 900 million Covaxin vaccines

Bharat Biotech to make 900 million Covaxin vaccines

Rediff.com   1 Jun 2021

500 million doses per annum from its two sites in Hyderabad and 200 million doses each from its Ankleshwar and Kolar facilities.

Despite multiple Covid deaths, UP villages in denial

Despite multiple Covid deaths, UP villages in denial

Rediff.com   1 Jun 2021

Hardly anyone wears a mask and most brush off concerns over a pandemic. It is not just scepticism over the existence of the pandemic. A common refrain across villages is the fear of vaccines, reports Ruchika Chitravanshi.

DRDO's Covid drug: Benefits. Concerns

DRDO's Covid drug: Benefits. Concerns

Rediff.com   31 May 2021

Commercial launch and supply to major government and private hospitals is expected in mid-June.

'India must do 7 million vaccinations a day'

'India must do 7 million vaccinations a day'

Rediff.com   22 May 2021

'If you approached it with that level of aggression in 100 days, you would have vaccinated more than half of your country.' 'On a mass scale you will be able to eliminate that wave.'

Self-use Covid-19 testing kits to be available at stores for Rs 250

Self-use Covid-19 testing kits to be available at stores for Rs 250

Rediff.com   21 May 2021

Pune's Mylab Discovery Solutions' CoviSelf, which gives results in 15 minutes, gets ICMR nod

Cipla ready to partner in Covid vaccine distribution

Cipla ready to partner in Covid vaccine distribution

Rediff.com   17 May 2021

However, Cipla was very clear it does not want to get into vaccine manufacturing.

Covaxin output scaled up to 500 million jabs a year: Bharat Biotech

Covaxin output scaled up to 500 million jabs a year: Bharat Biotech

Rediff.com   17 May 2021

This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.

Govt hopeful of vaccinating adult population by December

Govt hopeful of vaccinating adult population by December

Rediff.com   15 May 2021

India expects 2.16 billion doses of Covid-19 vaccines between August and December, including the jabs that are currently in clinical trials, reports Sohini Das

Private hospitals may import Covid vaccines

Private hospitals may import Covid vaccines

Rediff.com   15 May 2021

Apollo Hospitals and Fortis Healthcare are open to importing vaccines.

Sputnik V vaccine to be available in India from next week: Govt

Sputnik V vaccine to be available in India from next week: Govt

Rediff.com   14 May 2021

India is expecting 156 million doses of the vaccine from August to September, reports Ruchika Chitravanshi.

Prices of key Covid bulk drugs shoot up as demand rises

Prices of key Covid bulk drugs shoot up as demand rises

Rediff.com   12 May 2021

The API of Paracetamol, a fever and pain medication, has grown 25 per cent from Rs 450-480 per kg in December 2020 to Rs 580-600 per kg in April. When compared to the pre-Covid prices of December 2019, the surge is much steeper -- around 140 per cent, reports Sohini Das.

With Covid surge, FabiFlu becomes most sold drug in India

With Covid surge, FabiFlu becomes most sold drug in India

Rediff.com   11 May 2021

Drugs that are used to treat Covid or used by people as immunity boosters have seen a jump in sales and, in turn, rankings.

COVID-19 second wave: Delays in RT-PCR tests

COVID-19 second wave: Delays in RT-PCR tests

Rediff.com   9 May 2021

While there is a shortage of testing kits, manpower and capacities, India does not have other scalable testing options.